The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma

Neuroblastomas (NBs) harboring activating point mutations in Anaplastic Lymphoma Kinase (ALK) are differentially sensitive to the ALK inhibitor crizotinib, with certain mutations conferring intrinsic crizotinib resistance. To overcome this clinical obstacle, our goal was to identify inhibitors with...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Discov
Main Authors: Infarinato, Nicole R., Park, Jin H., Krytska, Kateryna, Ryles, Hannah T., Sano, Renata, Szigety, Katherine M., Li, Yimei, Zou, Helen Y., Lee, Nathan V., Smeal, Tod, Lemmon, Mark A., Mossé, Yael P.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4707106/
https://ncbi.nlm.nih.gov/pubmed/26554404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-1056
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items